BioAge Labs is a clinical-stage biotechnology company developing novel therapeutic targets and drug candidates for metabolic diseases by decoding the biology of aging. Headquartered in Emeryville, California, the company applies a data-driven approach to understanding the biological foundations of human aging.

Research Platform

BioAge’s proprietary discovery platform integrates over 65 million molecular measurements derived from more than 45 years of human aging data. By analyzing mechanisms linked to human lifespan and longevity, the platform identifies new biological pathways underlying age-related metabolic disorders. These insights guide target identification, drug discovery, and early clinical development efforts aimed at slowing or reversing age-related decline.

Clinical Programs

BioAge’s lead program, azelaprag, is a first-in-class, oral APJ receptor agonist being developed for the treatment of obesity in older adults. It is currently in Phase 2 clinical trials in combination with tirzepatide, an incretin-based therapy. Preclinical studies demonstrate that activation of the apelin/APJ signaling pathway increases energy expenditure and mimics the biological effects of exercise, offering a pharmacological parallel to the combined benefits of diet and physical activity.

Another key program, BGE-102, is an orally available, CNS-penetrant NLRP3 inhibitor designed to treat conditions driven by chronic inflammation, such as obesity and neuroinflammatory disorders. In preclinical models, BGE-102 produced dose-dependent weight loss as a monotherapy and achieved synergistic efficacy when combined with incretin drugs. Phase 1 clinical data are expected by the end of 2025.

Scientific and Corporate Structure

BioAge’s scientific strategy is grounded in insights derived from human longevity datasets, enabling the identification of molecular networks involved in cardiometabolic and neurodegenerative diseases.

The leadership team includes seasoned biopharma executives with over 95 regulatory drug approvals collectively. The company is led by Kristen Fortney, PhD (CEO and Co-Founder), Eric Morgen, MD (COO), and Paul Rubin, MD (CMO), who oversee BioAge’s strategic, operational, and clinical directions.

BioAge promotes an inclusive and supportive workplace culture, offering comprehensive healthcare coverage (medical, dental, and vision), childcare and fertility assistance, employer-matched 401(k) retirement plans, and professional development programs. The company emphasizes diversity, equity, and inclusion as core institutional values.